This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Join Mailing List   |   Jobs   |   Print Page   |   Contact Us   |   Sign In   |   Join
News & Press: Journals

New SSC guidelines released by JTH

Tuesday, December 22, 2015   (0 Comments)
Share |

The Journal of Thrombosis and Haemostasis (JTH) has accepted the following articles on recommendations from the Scientific and Standardization Committee (SSC) Subcommittees of the ISTH:

Subcommittee on Control of Anticoagulation: When and how to use antidotes for the reversal of direct oral anticoagulants
The direct oral anticoagulants (DOACs), which include dabigatran, rivaroxaban, apixaban, and edoxaban, are licensed for stroke prevention in patients with atrial fibrillation and for prevention and treatment of venous thromboembolism. As a class, the DOACs are at least as effective as vitamin K antagonists (VKAs), but are associated with less life-threatening bleeding, particularly intracranial hemorrhage. Although all anticoagulants can produce bleeding, the outcomes of major bleeds with DOACs are no worse than those with VKAs even in the absence of clinically available antidotes. Nonetheless, antidotes for the DOACs would be useful as one component of strategies for management of serious bleeding, or for rapid reversal of the DOACs prior to urgent interventions. Read more.

Membership Management Software Powered by YourMembership  ::  Legal